Biobanks - 2012 Year Book

GBI Research, the leading business intelligence provider, has released its latest report, “Biobanks - 2012 Year Book”. It provides key data, information and analysis of 37 of the world’s major biobanks. The report provides information on population-based biobanks, disease based biobanks, brain biobanks, stem cell biobanking, twin registries, children biobanks and many national biobanks. It also provides comprehensive analysis of funding, harmonization, the cost of biobanking, and partnership structure. In addition, the report reviews the factors determining the success and failure of biobanks.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.

Biobanking is a relatively new field with promising potential. It presents a host of opportunities and challenges. Funding patterns have changed as biobanks have evolved; in a comparative study of more than 100 biobanks around the world, the majority of biobanks were found to be stand-alone, and were entirely funded by the government of the country. Around 70% of biobanks are stand-alone,
whereas only 30% are partnered with other biobanks or institutions. With globalization and a growing interest in trans-national sharing of biobank resources, there is an increasing push to harmonize biobank processes and regulations. The process of setting up a new biobank is the most costly phase of a biobank’s development and lifespan. The maintenance cost of a biobank is marginal compared to the cost of set-up.

Scope

- A comprehensive study of 37 major biobanks in the world along with the current trends in biobanking.

- A comparative study of the major issues concerning biobanks including funding, harmonization, the cost of biobanking, partnership structure, and regulatory and ethical issues.

- In-depth analysis of the major developments in the leading segments of biobanks with key emphasis on major challenges in the biobanking sector.

Reasons to buy

- Evaluate major biobanks in the world, their service providers, research collaborations and private sector involvement.

- Analyze issues of funding, harmonization, the cost of biobanking, and partnership structure that determine strength and limitation of a biobank.

- Develop strategic initiatives by understanding the key focus of research of the leading biobanks.

- Accelerate and strengthen your market position by identifying key biobanks for mergers, acquisitions and strategic partnerships to accelerate research and development.

- Devise better strategies through the understanding of key drivers and barriers in the market.

- Develop understanding on recent developments in biobanking regulatory frameworks and ethical issues like informed consent, withdrawal of ownership, confidentiality and commercialization.
SHOW LESS
READ MORE >

The increase in the number of biobanks around the world has played an important role in fostering drug discovery, but tissue sample availability and limited inter-facility co-operation is threatening to hamper further progress, warns a new report by healthcare industry experts GBI Research.

According to the report*, biobanks have multiplied significantly since the 1970’s, and have become integral to research facilities around the globe. The period 1990-1999 saw the most significant percentage increase, at 42%. Growth in 2000 to 2009 was almost as impressive, with a 36% increase in biobanks.

These bio-repositories have become increasingly important with the expanding popularity of contemporary research into personalized medications and genomics, but a lack of particular storage types and specific tissue samples are major issues affecting the effectiveness of biobanks worldwide.

Tumor Tissue Repositories (TTR), for example, are a source of brain tumor samples that are experiencing difficulties in terms of supply. Normal brain samples to be used as control subjects are lacking, making comparative study ever more difficult.

However, there is an ongoing push toward harmonization – the large-scale sharing of data and statistical analyses that is allowing bio-repositories to benefit from the resources of others.

According to GBI Research, fruitful analyses will depend on the ability to harmonize and standardize the collection, storage, and management of data and bio-samples across biobanking studies.

Yet, while many international biobanks, such as P3G (Public Population Program in Genomics), BBMRI (Biobanking and BioMolecular Resources Research Infrastructure) and UKDBN (United Kingdom DNA Banking Network), are already involved in harmonization programs, several biobanks are still to join.

GBI Research states that, out of over 100 biobanks, the majority of facilities are stand-alone and receive all of their funding from the government. These made up 68% of the global total for 2010, while the remaining 32% were partnered with other biobanks or institutions.

* Biobanks - 2012 Year Book

This report provides key data, information and analysis of 37 of the world’s major biobanks. It also provides information on population-based biobanks, disease based biobanks, brain biobanks, stem cell biobanking, twin registries, children biobanks and many national biobanks.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.

Quick Help:
The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.